摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5,5-trimethyl-6H-cyclopenta[b]thiophen-4-one | 881190-06-3

中文名称
——
中文别名
——
英文名称
2,5,5-trimethyl-6H-cyclopenta[b]thiophen-4-one
英文别名
——
2,5,5-trimethyl-6H-cyclopenta[b]thiophen-4-one化学式
CAS
881190-06-3
化学式
C10H12OS
mdl
——
分子量
180.271
InChiKey
ADBZHUVVENCETC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    45.3
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • [EN] PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS<br/>[FR] PYRIDAZINONES ET LEUR UTILISATION COMME INHIBITEURS DE LA BTK
    申请人:CGI PHARMACEUTICALS INC
    公开号:WO2010056875A1
    公开(公告)日:2010-05-20
    Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    本文描述了抑制Btk的化合物(I)。描述了包含至少一种化合物(I)的药物组合物,以及至少一种从载体、辅料和赋形剂中选择的药用可接受载体。描述了治疗对Btk活性和/或B细胞活性抑制敏感的患者的方法。描述了检测样品中Btk存在的方法。
  • Cyclic amine derivative or salt thereof
    申请人:Hayashibe Satoshi
    公开号:US20070197594A1
    公开(公告)日:2007-08-23
    Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro- 1 H-cyclopenta[1]naphthalene) via X 1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.
    提供的化合物是NMDA受体拮抗剂,具有广泛的安全边界,并可用作治疗或预防阿尔茨海默病、脑血管性痴呆、帕森病、缺血性卒中、疼痛等药物。具体提供的是胺衍生物或其盐,其特点在于其中含有胺基结构A,通过X1(键或低碳烷基)与2-或3-环状紧缩环(例如烷、四氢酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-并[4,5-b]呋喃、2,3-二氢-1H-环戊[1]萘烷)结合;以及含有它作为有效成分的NMDA受体拮抗剂。
  • CYCLIC AMINE DERIVATIVE OR SALT THEREOF
    申请人:Astellas Pharma Inc.
    公开号:EP1795524A1
    公开(公告)日:2007-06-13
    Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro-1H-cyclopenta[1]naphthalene) via X1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.
    本发明提供的化合物是一种具有广泛安全范围的 NMDA 拮抗剂,可作为阿尔茨海默病、脑血管痴呆症、帕森病、缺血性脑中风、疼痛等的治疗剂或预防剂。具体而言,提供了一种胺衍生物或其盐,其特征在于其中的含胺结构 A 与 2-或 3-环缩合环(如茚满、四烯酮、4-环缩合环、5-环缩合环、6-环缩合环、7-环缩合环、8-环缩合环、9-环缩合环)结合、、四酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-并[4,5-b]呋喃、2,3-二氢-1H-环戊并[1])通过 X1(键或低级亚烷基)结合;以及含有它作为其活性成分的 NMDA 拮抗剂。
查看更多

同类化合物

酮替芬EP杂质A 酮替芬 苯噻啶苹果酸盐 苯噻啶盐酸盐 苯噻啶 益托洛替芬 富马酸酮替芬 去甲酮替芬富马酸氢盐 乙基2-[(乙基氨基甲硫杂酰)氨基]-5,6,7,8-四氢-4H-环庚三烯并[b]噻吩-3-羧酸酯 [2,3-d]噻吩并环庚三烯酮 9-氧代酮替芬 9,10-二溴-9,10-二氢-4H-苯并[4,5]环庚并[1,2-b]噻吩-4-酮 9,10-二氧代酮替芬 9, 10-二氢-4H-苯并[4, 5]环庚三烯[1, 2-b]噻吩-4-酮 6H-环庚三烯并[c]噻吩-6-酮,1,3,5,7-四甲基- 5,6,7,8-四氢-4h-环庚基[b]噻吩-2-羧酸 5,6,7,8-四氢-4H-环庚[b]噻吩-2-羧酸酰肼 4H-环庚三烯并[b]噻吩-3-羧酸,5,6,7,8-四氢-2-[3-(羟甲基)-5-甲基-4H-1,2,4-三唑-4-基]-,甲基酯 4-羟基酮替芬 4-(哌啶-4-亚基)-4H-苯并[4,5]环庚三烯并[1,2-B]噻吩-10(9H)-酮 4-(3'-甲基氨基丙基亚基)-9,10-二氢-4H-苯并(4,5)环庚并(1,2-b)噻吩 4,9-二氢-4-(1-甲基-4-哌啶基亚基)-10H-苯并[4,5]环庚三烯并[1,2-b]噻吩-10-酮 N-氧化物; 酮替芬 N-氧化物 2-溴-9,10-二氢-4H-苯并(4,5)环庚并(1,2-b)噻吩-4-酮 2-氯-N-(3-氰基-5,6,7,8-四氢-4H-环戊并[b]噻吩-2-基)-乙酰胺 2-氨基环庚烷并[B]噻吩-3-羧酸乙酯 2-氨基-N-甲基-5,6,7,8-四氢-4H-环庚并[b]噻吩-3-甲酰胺 2-氨基-N-乙基-5,6,7,8-四氢-4H-环庚并[b]噻吩-3-甲酰胺 2-氨基-5,6,7,8-四氢-4H-环庚基[b]噻吩-3-羧酰胺 2-氨基-5,6,7,8-四氢-4H-环庚基[b]噻吩-3-甲腈 2-氨基-5,6,7,8-四氢-4H-环庚[B]噻吩-3-甲酸甲酯 2-乙酰氨基-5,6,7,8-四氢-4H-环庚并[b]噻吩-3-羧酸 2-[(3-氯-1-氧代丙基)氨基]-5,6,7,8-四氢-4H-环庚并[b]噻吩-3-羧酸乙酯 2-(2-氯乙酰基氨基)-5,6,7,8-四氢-4H-环庚[b]噻吩-3-羧酸乙酯 10-甲氧基-4H-苯并[4,5]环庚三烯并[1,2-b]噻吩-4-酮 10-甲氧基-4-(1-甲基-4-哌啶基)-4H-苯并[4,5]环庚三烯并[1,2-B]噻吩-4-醇 1,3-二氢-1-[1-[(5,6,7,8-四氢-4H-环庚[b]噻吩-2-基)羰基]-4-哌啶基]-2H-苯并咪唑-2-酮 (3E)-3-(9,10-二氢-4H-苯并[4,5]环庚三烯并[1,2-b]噻吩-4-亚基)-N,N-二甲基丙烷-1-胺 (+/-)-10-<3-Dimethylamino-propyl>-4,5-dihydro-10H-benzo<5,6>cyclohepta<1,2-b>thiophen-10-ol methyl 2-[3-(acetylamino)-6-methyl-7-oxo-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl]acetate 10-<3-Dimethylamino-propyliden>-4,5-dihydro-10H-benzo<5,6>-cyclohepta<1,2-b>thiophen ethyl 3-[4-(1-methylpiperidin-4-ylidene)-10-oxo-9,10-dihydro-4H-1-thiabenzo[f]azulen-2-yl]acrylate 2-t-butoxycarbonylamino-4-(1-methylpiperidin-4-ylidene)-9,10-dihydro-4H-1-thiabenzo[f]azulene ethyl 4-[1-(2-ethoxyethyl)piperidin-4-ylidene]-9,10-dihydro-4H-1-thiabenzo[f]azulene-2-carboxylate hydrochloride Ethyl 4-(1-propylpiperidin-4-ylidene)-9,10-dihydro-4H-1-thiabenzo[f]azulene-2-carboxylate hydrochloride 4-(6-chloro-2-methyl-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-1-methyl-piperidine methyl 2-[2-(acetylamino)-6-methyl-7-oxo-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl]acetate 2-ureidomethyl-4-(1-methylpiperidin-4-ylidene)-9,10-dihydro-4H-1-thiabenzo[f]azulene 2-[2-(9,10-dihydro-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-ethyl]-piperidine-1-carboxylic acid ethyl ester 4-[1-(2-ethoxyethyl)piperidin-4-ylidene]-9,10-dihydro-4H-1-thiabenzo[f]azulene-2-carboxylic acid